← back to search

Ryan K. Shields

University of Pittsburgh · US
Area of research
Molecular Medicine · Pharmacology
Research interest
Research interests include Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance, and Antifungal resistance and susceptibility.
h-index
58
citations
10,542
works
325
NIH funding
primary concept
email

Recent publications

Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE)
Antimicrobial Agents and Chemotherapy 2025cited by 2position: lastdoi
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study
The Lancet Infectious Diseases 2024cited by 53position: firstdoi
Navigating Available Treatment Options for Carbapenem-Resistant<i>Acinetobacter baumannii-calcoaceticus</i>Complex Infections
Clinical Infectious Diseases 2023cited by 131position: firstdoi
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
Infectious Diseases and Therapy 2021cited by 67position: middledoi
Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017
Clinical Infectious Diseases 2020cited by 66position: lastdoi
Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube
Journal of Antimicrobial Chemotherapy 2020cited by 22position: middledoi
Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis
International Journal of Antimicrobial Agents 2019cited by 26position: middledoi
Pharmacokinetics and Dialytic Clearance of Isavuconazole during <i>In Vitro</i> and <i>In Vivo</i> Continuous Renal Replacement Therapy
Antimicrobial Agents and Chemotherapy 2019cited by 17position: middledoi
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Antimicrobial Agents and Chemotherapy 2018cited by 285position: firstdoi
Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms
Journal of Antimicrobial Chemotherapy 2018cited by 17position: middledoi
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Antimicrobial Agents and Chemotherapy 2017cited by 483position: firstdoi
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Antimicrobial Agents and Chemotherapy 2016cited by 483position: firstdoi
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
Clinical Infectious Diseases 2016cited by 424position: firstdoi
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Clinical Infectious Diseases 2015cited by 398position: middledoi
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
Antimicrobial Agents and Chemotherapy 2015cited by 66position: middledoi
Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States
Journal of Clinical Microbiology 2014cited by 66position: middledoi
Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates
Antimicrobial Agents and Chemotherapy 2014cited by 60position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

M. Hong Nguyen · University of Pittsburgh9 papers (2014–2020)Cornelius J. Clancy · University of Pittsburgh8 papers (2014–2020)Liang Chen · South China Agricultural University4 papers (2016–2018)Yohei Doi · University of Pittsburgh4 papers (2015–2017)Ellen G. Press · University of Pittsburgh4 papers (2016–2018)Barry N. Kreiswirth · Center for Discovery4 papers (2016–2018)Brian A. Potoski · University of Pittsburgh3 papers (2014–2017)Eric Wenzler · University of Illinois Chicago3 papers (2018–2019)Kevin A. Meyer · University of Illinois Chicago2 papers (2018–2019) · 2 papers (2020–2025)Lloyd Clarke · University of Pittsburgh Medical Center2 papers (2014–2020)Ryan Rivosecchi · University of Pittsburgh Medical Center2 papers (2019–2020)Rachel V Marini · University of Pittsburgh Medical Center2 papers (2017–2020)Erin K. McCreary · University of Pittsburgh Medical Center2 papers (2020–2025)Lindsey R. Baden · Harvard University1 papers (2014–2014)Jovan Borjan · University of Illinois Chicago1 papers (2019–2019)José A. Vázquez · Augusta University1 papers (2014–2014)Sharon Chen · Northwell Health1 papers (2014–2014)Maha Assi · University of Kansas1 papers (2014–2014)Lauren M. Sacha · University of Pittsburgh Medical Center1 papers (2020–2020)